The hypothesis tested during Phase I was that an ideal filtration marker can be labeled with a metal that when neutron activated generates a strong photon signal suitable for the measurement of glomerular filtration rate (GFR). We successfully proved our hypothesis and demonstrated concept feasibility. The results of our Phase I study have identified three promising agents. Our Phase II research will expand on this work by directly comparing our novel method to traditional methods of measuring GFR (sodium iothalanate (I-125) and 51-Cr-EDTA) using an in vivo rabbit model. In addition, Phase II will evaluate the biodistribution of each agent and will initiate preclinical toxicology studies necessary to carry the project forward to Phase lIl. Our goal is to identify an ideal filtration marker that can be labeled with two different stable isotopes. As a result, we can provide a non-radioactive GFR assay kit that is safe, easy-to-use, accurate, and cost-effective, while providing a diagnostic modality that is versatile for a wide range of clinical and research applications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44DK057502-02A2
Application #
6582415
Study Section
Special Emphasis Panel (ZRG1-SSS-7 (10))
Program Officer
Moxey-Mims, Marva M
Project Start
2004-08-01
Project End
2006-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
2
Fiscal Year
2004
Total Cost
$385,468
Indirect Cost
Name
Biopal, Inc
Department
Type
DUNS #
009796223
City
Worcester
State
MA
Country
United States
Zip Code
01603